Jun 15, 2026 | CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head

CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS vaccine crashes, and FDA approves Truqap in prostate cancer and Tzield for pediatric T1D.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, CMS, Medicare drug price negotiation, IRA, Keytruda, pembrolizumab, Opdivo, nivolumab, subcutaneous, Merck, Bristol Myers Squibb, Takeda, zasocitinib, Sotyktu, deucravacitinib, TYK2, Novartis, Avidity Biosciences, del-brax, RNA therapeutics, Elicio Therapeutics, KRAS, cancer vaccine, ELI-002, pancreatic cancer, AstraZeneca, Truqap, capivasertib, prostate cancer, PTEN, Sanofi, Tzield, teplizumab, type 1 diabetes, Welireg, belzutifan, kidney cancer, J&J, Talvey, Darzalex Faspro, multiple myeloma, Summit Therapeutics, ivonescimab, oveporexton, narcolepsy, SLEEP 2026, Gan & Lee, bofanglutide, obesity, GLP-1, Eisai, Leqembi, Lilly, BMS